retatrutide mechanism gip glp-1 glucagon triple agonist Reta clinical trial data & dosing β a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health β targeting GLP-1, π¨ Today, retatrutide, the GIP/GLP-1/glucagon
Pay in 4 interest-free payments of $7.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Sep 6 - Sep 11


























